User contributions for Tejasvi Aryaputra

23:0723:07, 7 February 2023 diff hist +15,078‎ Lybalvi (Olanzapine and Samidorphan) ‎No edit summary current

17:0117:01, 20 January 2023 diff hist +3,741‎ N Lybalvi (Olanzapine and Samidorphan) ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Lybalvi |aOrAn=a |drugClass=combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist |indicationType=treatment |indication=schizophrenia and certain aspects of bipolar I disorder |hasBlackBoxWarning=Yes |adverseReactions=somnolence, headache, [[dry mouth], and weight increase for patients with schizophrenia. Dizziness, asthenia, constipation, [..."
16:1016:10, 20 January 2023 diff hist 0‎ N File:Package Insert Pt.2.png ‎No edit summary current
16:1016:10, 20 January 2023 diff hist 0‎ N File:Package Insert Pt.1.png ‎No edit summary current
16:1016:10, 20 January 2023 diff hist 0‎ N File:Drug Label 2.png ‎No edit summary current
16:1016:10, 20 January 2023 diff hist 0‎ N File:Drug Label 1.png ‎No edit summary current
16:1016:10, 20 January 2023 diff hist 0‎ N File:Drug Info.png ‎No edit summary current
16:1016:10, 20 January 2023 diff hist 0‎ N File:Structure 2.png ‎No edit summary current
16:0916:09, 20 January 2023 diff hist 0‎ N File:Structure 1.png ‎No edit summary current
16:0916:09, 20 January 2023 diff hist 0‎ N File:Table 5 Clinical Data Trial 3.png ‎No edit summary current
16:0916:09, 20 January 2023 diff hist 0‎ N File:Table 4 Clinical Data Trial 1 and 2.png ‎No edit summary current
16:0916:09, 20 January 2023 diff hist 0‎ N File:Table 3 Coadmininstered Drugs.png ‎No edit summary current
16:0916:09, 20 January 2023 diff hist 0‎ N File:Table 2 Adverse Reaction Trial 3.png ‎No edit summary current
16:0916:09, 20 January 2023 diff hist 0‎ N File:Ibrexafungerp Table 1 Adverse Reactions (Trials 1 and 2).png ‎No edit summary current
15:5115:51, 20 January 2023 diff hist +5,623‎ Ibrexafungerp ‎No edit summary current

06:0006:00, 18 January 2023 diff hist +4,749‎ Ibrexafungerp ‎No edit summary
04:5604:56, 18 January 2023 diff hist +2,856‎ Aducanumab-avwa ‎No edit summary current
04:5404:54, 18 January 2023 diff hist +2,211‎ Aducanumab-avwa ‎No edit summary

05:4805:48, 11 January 2023 diff hist +8,233‎ N Ibrexafungerp ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Ibrexafungerp |aOrAn=a |drugClass=triterpenoid antifungal |indicationType=treatment |indication=vulvovaginal candidiasis |hasBlackBoxWarning=Yes |adverseReactions=nausea, dizziness, diarrhea, vomiting, and abdominal pain |blackBoxWarningTitle='''RISK OF EMBRYO-FETAL TOXICITY''' |blackBoxWarningBody= *BREXAFEMME is contraindicated in pregn..."

21:5921:59, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Table 8 Study 2 Biomarkers.png ‎No edit summary current
21:5921:59, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Table 7 Clinical Results Study 1.png ‎No edit summary current
21:5921:59, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Table 6 Study 1 Biomarkers.png ‎No edit summary current
21:5921:59, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Table 5 Adverse Reactions.png ‎No edit summary current
21:5921:59, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Table 4 ARIA Classification.png ‎No edit summary current
21:5821:58, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Table 3 Dosing Modifciations.png ‎No edit summary current
21:5821:58, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Table 2 Dosing Monitoring.png ‎No edit summary current
21:5821:58, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Table 1 Dosing.png ‎No edit summary current
21:5821:58, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Study 3 Biomarkers.png ‎No edit summary current
21:5721:57, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Package Insert Cont..png ‎No edit summary current
21:5721:57, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Package Insert.png ‎No edit summary current
21:5721:57, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Figure 4 Clinical Studies.png ‎No edit summary current
21:5721:57, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Figure 3 Clinical Studies.png ‎No edit summary current
21:5721:57, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Figure 2 Clinical Studies.png ‎No edit summary current
21:5721:57, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Figure 1 Clinical Studies.png ‎No edit summary current
21:5621:56, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Drug Label (3 mL).png ‎No edit summary current
21:5621:56, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Drug Label (1.7 mL).png ‎No edit summary current
21:5621:56, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Drug Cont..png ‎No edit summary current
21:5621:56, 10 January 2023 diff hist 0‎ N File:Aducanumab-avwa Drug Info .png ‎No edit summary current

17:3117:31, 5 January 2023 diff hist +1‎ Aducanumab-avwa ‎No edit summary
17:2917:29, 5 January 2023 diff hist +18,474‎ N Aducanumab-avwa ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Aducanumab-avwa |aOrAn=an |drugClass=amyloid beta-directed antibody |indicationType=treatment |indication=treat Alzheimer’s disease |adverseReactions=ARIA-H microhemorrhage, fall, ARIA-Edema, ARIA-H superficial siderosis, and headache |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:..."
05:4305:43, 5 January 2023 diff hist +2,942‎ Asparaginase erwinia chrysanthemi (recombinant)-rywn ‎No edit summary current

13:4613:46, 3 January 2023 diff hist 0‎ N File:Rylaze Table 5 Clinical Studies.png ‎No edit summary current
13:4613:46, 3 January 2023 diff hist 0‎ N File:Rylaze Table 4 Pharmacokinetics.png ‎No edit summary current
13:4613:46, 3 January 2023 diff hist 0‎ N File:Rylaze Table 3 Adverse Reactions.png ‎No edit summary current
13:4613:46, 3 January 2023 diff hist 0‎ N File:Rylaze Table 2 Dosage Modifications.png ‎No edit summary current
13:4613:46, 3 January 2023 diff hist 0‎ N File:Rylaze Table 1 Dosages.png ‎No edit summary current
13:4613:46, 3 January 2023 diff hist 0‎ N File:Rylaze Drug Label 2.png ‎No edit summary current
13:4613:46, 3 January 2023 diff hist 0‎ N File:Rylaze Drug Label 1.png ‎No edit summary current
13:4613:46, 3 January 2023 diff hist 0‎ N File:Rylaze Drug Insert.png ‎No edit summary current
13:3613:36, 3 January 2023 diff hist +84‎ Asparaginase erwinia chrysanthemi (recombinant)-rywn ‎No edit summary
13:3113:31, 3 January 2023 diff hist +4,725‎ Asparaginase erwinia chrysanthemi (recombinant)-rywn ‎No edit summary

21:1621:16, 29 December 2022 diff hist +5,755‎ Asparaginase erwinia chrysanthemi (recombinant)-rywn ‎No edit summary
19:1219:12, 29 December 2022 diff hist +6,304‎ N Asparaginase erwinia chrysanthemi (recombinant)-rywn ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Asparaginase erwinia chrysanthemi (recombinant)-rywn |aOrAn=an |drugClass=asparagine specific enzyme |indicationType=treatment |indication=acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimen |adverseReactions=musculoskeletal pain, febrile neutropenia, hypokalemia, abnorm..."

00:0900:09, 12 September 2022 diff hist +5,125‎ Finerenone ‎No edit summary current

00:1600:16, 6 September 2022 diff hist 0‎ N File:Finerenone Table 4 Clinical Studies.png ‎No edit summary current
00:1500:15, 6 September 2022 diff hist 0‎ N File:Finerenone Table 3 Adverse Reactions.png ‎No edit summary current
00:1500:15, 6 September 2022 diff hist 0‎ N File:Finerenone Table 2 Dosage Adjustments.png ‎No edit summary current
00:1500:15, 6 September 2022 diff hist 0‎ N File:Finerenone Table 1 Dosage.png ‎No edit summary current
00:1500:15, 6 September 2022 diff hist 0‎ N File:Finerenone Structure 2.png ‎No edit summary current
00:1500:15, 6 September 2022 diff hist 0‎ N File:Finerenone Structure.png ‎No edit summary current
00:1500:15, 6 September 2022 diff hist 0‎ N File:Finerenone Figure 2 Clinical Studies.png ‎No edit summary current
00:1500:15, 6 September 2022 diff hist 0‎ N File:Finerenone Figure 1 Clincal Studies.png ‎No edit summary current
00:1500:15, 6 September 2022 diff hist 0‎ N File:Finerenone Drug Label (20 mg).png ‎No edit summary current
00:1500:15, 6 September 2022 diff hist 0‎ N File:Finerenone Drug Label (10 mg).png ‎No edit summary current
00:1500:15, 6 September 2022 diff hist 0‎ N File:Finerenone Drug Info Pt.3.png ‎No edit summary current
00:1400:14, 6 September 2022 diff hist 0‎ N File:Finerenone Drug Info Pt.2.png ‎No edit summary current
00:1400:14, 6 September 2022 diff hist 0‎ N File:Finerenone Drug Info.png ‎No edit summary current

21:0421:04, 5 September 2022 diff hist +2,463‎ Finerenone ‎No edit summary
05:4005:40, 5 September 2022 diff hist +10,703‎ N Finerenone ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Finerenone |aOrAn=a |drugClass=mineralocorticoid receptor antagonist |indicationType=prophylaxis |indication=the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes |adverseReactions=hypotension, hyperkalemia, and hyponatremia |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''<span style="color:#FF00..."
02:3402:34, 5 September 2022 diff hist +4,777‎ Fexinidazole ‎No edit summary current
02:1102:11, 5 September 2022 diff hist 0‎ N File:Fexinidazole Table 6 Success Rate.png ‎No edit summary current
02:1102:11, 5 September 2022 diff hist 0‎ N File:Fexinidazole Table 5 Pharmocokinetics.png ‎No edit summary current
02:1002:10, 5 September 2022 diff hist 0‎ N File:Fexinidazole Table 4 Drug Interactions Pt.4.png ‎No edit summary current
02:1002:10, 5 September 2022 diff hist 0‎ N File:Fexinidazole Table 3 Drug Interactions Pt.1.png ‎No edit summary current
02:1002:10, 5 September 2022 diff hist 0‎ N File:Fexinidazole Table 2 Adverse Reactions Pt.2.png ‎No edit summary current
02:1002:10, 5 September 2022 diff hist 0‎ N File:Fexinidazole Table 2 Adverse Reactions.png ‎No edit summary current
02:1002:10, 5 September 2022 diff hist 0‎ N File:Fexinidazole Table 1 Dosage.png ‎No edit summary current
02:1002:10, 5 September 2022 diff hist 0‎ N File:Fexinidazole Packaging Label.png ‎No edit summary current
02:1002:10, 5 September 2022 diff hist 0‎ N File:Fexinidazole Packaging Info Pt.2.png ‎No edit summary current
02:0902:09, 5 September 2022 diff hist 0‎ N File:Fexinidazole Packaging Info Pt.1.png ‎No edit summary current
02:0902:09, 5 September 2022 diff hist 0‎ N File:Fexinidazole Chemical Structure Pt.2.png ‎No edit summary current
02:0902:09, 5 September 2022 diff hist 0‎ N File:Fexinidazole Chemical Structure.png ‎No edit summary current
02:0802:08, 5 September 2022 diff hist +6,437‎ Belumosudil ‎No edit summary current
01:3201:32, 5 September 2022 diff hist +15,982‎ N Fexinidazole ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Fexinidazole |aOrAn=a |drugClass=nitroimidazole antimicrobial |indicationType=treatment |indication=human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense |adverseReactions=hypocalcemia, upper abdominal pain, insomnia, dyspepsia, decreased appetite, hyperkalemia, back pain, nausea, dizziness, asthenia, tremor, and headache...."

01:3401:34, 30 August 2022 diff hist 0‎ N File:Belumosudil Table 2 Adverse Reactions.png ‎No edit summary current
01:3301:33, 30 August 2022 diff hist 0‎ N File:Belumosudil Table 5 Clinical Data.png ‎No edit summary current
01:3201:32, 30 August 2022 diff hist 0‎ N File:Belumosudil Table 4 Patient Pop.png ‎No edit summary current
01:3201:32, 30 August 2022 diff hist 0‎ N File:Belumosudil Table 3 Lab Abnormalties.png ‎No edit summary current
01:3201:32, 30 August 2022 diff hist 0‎ N File:Belumosudil Table 2 Adverse Reactions Pt. 2.png ‎No edit summary current
01:3201:32, 30 August 2022 diff hist 0‎ N File:Belumosudil Table 1 Dosage.png ‎No edit summary current
01:3201:32, 30 August 2022 diff hist 0‎ N File:Belumosudil Structure 2.png ‎No edit summary current
01:3201:32, 30 August 2022 diff hist 0‎ N File:Belumosudil Structure.png ‎No edit summary current
01:3201:32, 30 August 2022 diff hist 0‎ N File:Belumosudil Package Insert Pt.2 .png ‎No edit summary current
01:3201:32, 30 August 2022 diff hist 0‎ N File:Belumosudil Package Insert.png ‎No edit summary current
01:3101:31, 30 August 2022 diff hist 0‎ N File:Belumosudil Drug Label.png ‎No edit summary current
01:3101:31, 30 August 2022 diff hist 0‎ N File:Belumosudil Drug Insert Pt.2.png ‎No edit summary current
01:3101:31, 30 August 2022 diff hist 0‎ N File:Belumosudil Drug Insert.png ‎No edit summary current
01:2501:25, 30 August 2022 diff hist +5,821‎ Odevixibat ‎No edit summary current
01:1301:13, 30 August 2022 diff hist 0‎ N File:Odevixibat Structure.png ‎No edit summary current
00:5500:55, 30 August 2022 diff hist +3,257‎ Belumosudil ‎No edit summary
00:2000:20, 30 August 2022 diff hist +11,664‎ N Belumosudil ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Belumosudil |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy |adverseReactions=dyspnea, asthenia, phosphate decrease, hypertension, cough, nausea, lymphocytes decreased, edema, diarrhea, glutamyl transferase increased,, hemorrhage, h..."
00:0000:00, 30 August 2022 diff hist +1‎ Odevixibat ‎No edit summary

00:3900:39, 25 August 2022 diff hist 0‎ N File:Odevixibat Table 4 Efficacy.png ‎No edit summary current
00:3800:38, 25 August 2022 diff hist 0‎ N File:Odevixibat Table 3 Adverse Reactions.png ‎No edit summary current
00:3800:38, 25 August 2022 diff hist 0‎ N File:Odevixibat Table 2 Liver Test.png ‎No edit summary current
00:3800:38, 25 August 2022 diff hist 0‎ N File:Odevixibat Table 1 Dosage.png ‎No edit summary current
00:3800:38, 25 August 2022 diff hist 0‎ N File:Odevixibat Package Label (1200 mcg).png ‎No edit summary current
00:3800:38, 25 August 2022 diff hist 0‎ N File:Odevixibat Package Label (600 mcg).png ‎No edit summary current
00:3800:38, 25 August 2022 diff hist 0‎ N File:Odevixibat Package Label (400 mcg).png ‎No edit summary current
00:3800:38, 25 August 2022 diff hist 0‎ N File:Odevixibat Package Label (200 mcg).png ‎No edit summary current
00:3700:37, 25 August 2022 diff hist 0‎ N File:Odevixibat Figure 1 Scratching.png ‎No edit summary current
00:3700:37, 25 August 2022 diff hist 0‎ N File:Odevixibat Drug Packaging Pt.4.png ‎No edit summary current
00:3700:37, 25 August 2022 diff hist 0‎ N File:Odevixibat Drug Packaging Pt.3.png ‎No edit summary current
00:3700:37, 25 August 2022 diff hist 0‎ N File:Odevixibat Drug Packaging Pt.2.png ‎No edit summary current
00:3700:37, 25 August 2022 diff hist 0‎ N File:Odevixibat Drug Packaging Pt.1.png ‎No edit summary current
00:2300:23, 25 August 2022 diff hist +2,329‎ Odevixibat ‎No edit summary

01:3301:33, 23 August 2022 diff hist +13,978‎ N Odevixibat ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Odevixibat |aOrAn=a |drugClass=ileal bile acid transporter inhibitor |indicationType=treatment |indication=pruritus |adverseReactions=abdominal pain,, fat-soluble vitamin deficiency, diarrhea, vomiting, and liver test abnormalities. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Cont..."

23:2823:28, 22 August 2022 diff hist −9‎ Anifrolumab-fnia ‎No edit summary current
01:2601:26, 22 August 2022 diff hist +4,685‎ Anifrolumab-fnia ‎No edit summary

18:2318:23, 5 August 2022 diff hist 0‎ N File:Anifrolumab-fnia Table 4 SRI.png ‎No edit summary current
18:2218:22, 5 August 2022 diff hist 0‎ N File:Anifrolumab-fnia Table 3 BICLA.png ‎No edit summary current
18:2218:22, 5 August 2022 diff hist 0‎ N File:Anifrolumab-fnia Table 2 Baseline.png ‎No edit summary current
18:2218:22, 5 August 2022 diff hist 0‎ N File:Anifrolumab-fnia Table 1 Adverse Reactions.png ‎No edit summary current
18:2218:22, 5 August 2022 diff hist 0‎ N File:Anifrolumab-fnia Package Insert 2.png ‎No edit summary current
18:2218:22, 5 August 2022 diff hist 0‎ N File:Anifrolumab-fnia Package Insert 1 .png ‎No edit summary current
18:2218:22, 5 August 2022 diff hist 0‎ N File:Anifrolumab-fnia Figure 1 Trial 3 Data.png ‎No edit summary current
18:2218:22, 5 August 2022 diff hist 0‎ N File:Anifrolumab-fnia Drug Packaging.png ‎No edit summary current
18:2218:22, 5 August 2022 diff hist 0‎ N File:Anifrolumab-fnia Drug Label.png ‎No edit summary current
17:5317:53, 5 August 2022 diff hist +716‎ Anifrolumab-fnia ‎No edit summary
15:5215:52, 5 August 2022 diff hist +2,709‎ Anifrolumab-fnia ‎No edit summary

20:4720:47, 3 August 2022 diff hist +4,937‎ Anifrolumab-fnia ‎No edit summary

20:0820:08, 2 August 2022 diff hist +2,465‎ Anifrolumab-fnia ‎No edit summary

20:4120:41, 1 August 2022 diff hist +4,591‎ Anifrolumab-fnia ‎No edit summary

19:0519:05, 28 July 2022 diff hist +2,592‎ Anifrolumab-fnia ‎No edit summary

14:5214:52, 26 July 2022 diff hist −8‎ Anifrolumab-fnia ‎No edit summary
14:5114:51, 26 July 2022 diff hist +1,325‎ N Anifrolumab-fnia ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Anifrolumab-fnia |aOrAn=a |drugClass=type I interferon receptor antagonist |indicationType=treatment |indication=moderate-to severe systemic lupus erythematousus along with standard therapy |adverseReactions=bronchitis, nasopharyngitis, herpes zoster, upper respiratory tract infections, infusion related reactions, and cough |blackBoxWarningTitle='''<span style="color:#FF0000..."
14:4414:44, 26 July 2022 diff hist +7,145‎ Avalglucosidase alfa-ngpt ‎No edit summary current

18:5118:51, 25 July 2022 diff hist 0‎ N File:Avalglucosidase alfa-ngpt Table 5 Walking.png ‎No edit summary current
18:5118:51, 25 July 2022 diff hist 0‎ N File:Avalglucosidase alfa-ngpt Table 4 FVC.png ‎No edit summary current
18:5018:50, 25 July 2022 diff hist 0‎ N File:Avalglucosidase alfa-ngpt Table 3 Antibodies.png ‎No edit summary current
18:5018:50, 25 July 2022 diff hist 0‎ N File:Avalglucosidase alfa-ngpt Table 2 Adverse Reactions.png ‎No edit summary current
18:5018:50, 25 July 2022 diff hist 0‎ N File:Avalglucosidase alfa-ngpt Table 1 Infusion Rate.png ‎No edit summary current
18:5018:50, 25 July 2022 diff hist 0‎ N File:Avalglucosidase alfa-ngpt Packaging Label 2.png ‎No edit summary current
18:5018:50, 25 July 2022 diff hist 0‎ N File:Avalglucosidase alfa-ngpt Packaging Label.png ‎No edit summary current
18:5018:50, 25 July 2022 diff hist 0‎ N File:Avalglucosidase alfa-ngpt Figure 2 Walking.png ‎No edit summary current
18:4918:49, 25 July 2022 diff hist 0‎ N File:Avalglucosidase alfa-ngpt Figure 1 FVC.png ‎No edit summary current
18:4918:49, 25 July 2022 diff hist 0‎ N File:Avalglucosidase alfa-ngpt Drug Packaging.png ‎No edit summary current
18:1418:14, 25 July 2022 diff hist +3,096‎ Avalglucosidase alfa-ngpt ‎No edit summary
16:3116:31, 25 July 2022 diff hist 0‎ Avalglucosidase alfa-ngpt ‎No edit summary
16:0116:01, 25 July 2022 diff hist +10,209‎ Avalglucosidase alfa-ngpt ‎No edit summary

18:0818:08, 22 July 2022 diff hist +1‎ Avalglucosidase alfa-ngpt ‎No edit summary
18:0618:06, 22 July 2022 diff hist +8,285‎ Avalglucosidase alfa-ngpt ‎No edit summary
14:1714:17, 22 July 2022 diff hist +2,100‎ N Avalglucosidase alfa-ngpt ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Avalglucosidase alfa-ngpt |aOrAn=a |drugClass=hydrolytic lysosomal glycogen-specific enzyme |indicationType=treatment |indication=late-onset Pompe disease |hasBlackBoxWarning=Yes |adverseReactions=erythema, pruritus, urticaria, nausea, headache, dizziness, paresthesia, myalgia, arthralgia, diarrhea, dyspnea, and vomiting |blackBoxWarningTitle='''<span..."
13:3913:39, 22 July 2022 diff hist +1‎ Belzutifan ‎No edit summary current
13:3713:37, 22 July 2022 diff hist +230‎ Belzutifan ‎No edit summary
13:2813:28, 22 July 2022 diff hist +5,079‎ Belzutifan ‎No edit summary

18:5518:55, 21 July 2022 diff hist 0‎ N File:Belzutifan Table 5 Efficacy Pt.2.png ‎No edit summary current
18:5518:55, 21 July 2022 diff hist 0‎ N File:Belzutifan Table 4 Efficacy.png ‎No edit summary current
18:5518:55, 21 July 2022 diff hist 0‎ N File:Belzutifan Table 3 Lab Abnormalities.png ‎No edit summary current
18:5518:55, 21 July 2022 diff hist 0‎ N File:Belzutifan Table 2 Adverse Reactions.png ‎No edit summary current
18:5418:54, 21 July 2022 diff hist 0‎ N File:Belzutifan Table 1 Dosage.png ‎No edit summary current
18:5418:54, 21 July 2022 diff hist 0‎ N File:Belzutifan Structure.png ‎No edit summary current
18:5418:54, 21 July 2022 diff hist 0‎ N File:Belzutifan Medical Guide Pt. 2.png ‎No edit summary current
18:5418:54, 21 July 2022 diff hist 0‎ N File:Belzutifan Medical Guide.png ‎No edit summary current
18:5418:54, 21 July 2022 diff hist 0‎ N File:Belzutifan Drug Label.png ‎No edit summary current
18:5318:53, 21 July 2022 diff hist 0‎ N File:Belzutifan Drug Information.png ‎No edit summary current
18:5318:53, 21 July 2022 diff hist 0‎ N File:Belzutifan Chemical Structure.png ‎No edit summary current
17:2717:27, 21 July 2022 diff hist +7,343‎ Belzutifan ‎No edit summary
13:2913:29, 21 July 2022 diff hist +480‎ Belzutifan ‎No edit summary

16:5916:59, 18 July 2022 diff hist +260‎ Belzutifan ‎No edit summary

20:0820:08, 15 July 2022 diff hist +5,498‎ Belzutifan ‎No edit summary

19:2019:20, 14 July 2022 diff hist +5,888‎ Belzutifan ‎No edit summary

18:4218:42, 13 July 2022 diff hist +1,282‎ N Belzutifan ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Belzutifan |aOrAn=a |drugClass=hypoxia-inducible factor inhibitor |indicationType=treatment |indication=von Hippel-Lindau disease under certain conditions |hasBlackBoxWarning=Yes |adverseReactions=headache, increased creatinine, nausea, anemia, decreased hemoglobin, dizziness, fatigue, and increased glucose |blackBoxWarningTitle='''TITLE</spa..."
13:2013:20, 13 July 2022 diff hist −407‎ Difelikefalin ‎No edit summary current
13:1713:17, 13 July 2022 diff hist +6,007‎ Difelikefalin ‎No edit summary

20:1420:14, 12 July 2022 diff hist 0‎ N File:Difelikefalin Table 3 Efficacy Results.png ‎No edit summary current
20:1420:14, 12 July 2022 diff hist 0‎ N File:Difelikefalin Table 2 Adverse Reactions.png ‎No edit summary current
20:1320:13, 12 July 2022 diff hist 0‎ N File:Difelikefalin Table 1 Dosing.png ‎No edit summary current
20:1320:13, 12 July 2022 diff hist 0‎ N File:Difelikefalin Structure 2.png ‎No edit summary current
20:1320:13, 12 July 2022 diff hist 0‎ N File:Difelikefalin Structure 1.png ‎No edit summary current
20:1320:13, 12 July 2022 diff hist 0‎ N File:Difelikefalin Packaging Label.png ‎No edit summary current
20:1320:13, 12 July 2022 diff hist 0‎ N File:Difelikefalin Drug Packaging.png ‎No edit summary current
20:1320:13, 12 July 2022 diff hist 0‎ N File:Difelikefalin Drug Label.png ‎No edit summary current
19:5819:58, 12 July 2022 diff hist +3,616‎ Difelikefalin ‎No edit summary
19:0619:06, 12 July 2022 diff hist +242‎ Difelikefalin ‎No edit summary
17:1417:14, 12 July 2022 diff hist +925‎ Difelikefalin ‎No edit summary

20:4820:48, 11 July 2022 diff hist +6,531‎ Difelikefalin ‎No edit summary
16:4616:46, 11 July 2022 diff hist +1,459‎ Difelikefalin ‎No edit summary

19:3419:34, 8 July 2022 diff hist +1,290‎ Difelikefalin ‎No edit summary

18:3718:37, 6 July 2022 diff hist +3,529‎ N Difelikefalin ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Difelikefalin |aOrAn=a |drugClass=kappa opioid receptor agonist |indicationType=treatment |indication=moderate-to-severe pruritus associated with chronic kidney disease in certain populations |adverseReactions=dizziness, somnolence, diarrhea, hyperkalemia, nausea, gait disturbances, and mental status change |blackBoxWarningTitle='''TITLE''..."

13:1413:14, 5 July 2022 diff hist +6,296‎ Lonapegsomatropin-tcgd ‎No edit summary current
13:0013:00, 5 July 2022 diff hist +707‎ Lonapegsomatropin-tcgd ‎No edit summary
12:3612:36, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Table 6 Catridges.png ‎No edit summary current
12:3612:36, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Table 5 Height SDS.png ‎No edit summary current
12:3612:36, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Table 4 High Velocity.png ‎No edit summary current
12:3612:36, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Table 3 Drug Interactions.png ‎No edit summary current
12:3512:35, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Table 2 Adverse Reactions.png ‎No edit summary current
12:3512:35, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Table 1 Dosage.png ‎No edit summary current
12:3512:35, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 13.3 Mg Pt.2.png ‎No edit summary current
12:3512:35, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 13.3 Mg Pt.1.png ‎No edit summary current
12:3512:35, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 11 Mg Pt.2.png ‎No edit summary current
12:3512:35, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 11 Mg Pt.1.png ‎No edit summary current
12:3312:33, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 9.1 Mg Pt.2.png ‎No edit summary current
12:3312:33, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 9.1 Mg Pt.1.png ‎No edit summary current
12:3212:32, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 7.6 Mg Pt.2.png ‎No edit summary current
12:3212:32, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 7.6 Mg Pt.1.png ‎No edit summary current
12:3212:32, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 6.3 Mg Pt.2.png ‎No edit summary current
12:3112:31, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 6.3 Mg Pt.1.png ‎No edit summary current
12:3112:31, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 5.2 Mg Pt.2.png ‎No edit summary current
12:3112:31, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 5.2 Mg Pt.1.png ‎No edit summary current
12:3112:31, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 4.3 Mg Pt.2.png ‎No edit summary current
12:3012:30, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 4.3 Mg Pt.1.png ‎No edit summary current
12:2912:29, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 3.6 Mg Pt.2.png ‎No edit summary current
12:2912:29, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 3.6 Mg Pt.1.png ‎No edit summary current
12:2912:29, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 3 Mg Pt.2.png ‎No edit summary current
12:2912:29, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Label 3 Mg Pt.1.png ‎No edit summary current
12:2912:29, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Information Pt.6.png ‎No edit summary current
12:2812:28, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Information Pt.5.png ‎No edit summary current
12:2812:28, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Information Pt.4.png ‎No edit summary current
12:2812:28, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Information Pt.3.png ‎No edit summary current
12:2812:28, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Information Pt.2.png ‎No edit summary current
12:2812:28, 5 July 2022 diff hist 0‎ N File:Lonapegsomatropin-tcgd Drug Information Pt.1.png ‎No edit summary current

04:1204:12, 4 July 2022 diff hist +2,525‎ Lonapegsomatropin-tcgd ‎No edit summary
03:3203:32, 4 July 2022 diff hist +4,740‎ Lonapegsomatropin-tcgd ‎No edit summary
00:3900:39, 4 July 2022 diff hist +907‎ Lonapegsomatropin-tcgd ‎No edit summary

20:1520:15, 1 July 2022 diff hist +7,316‎ Lonapegsomatropin-tcgd ‎No edit summary

20:5420:54, 27 June 2022 diff hist +4,627‎ Lonapegsomatropin-tcgd ‎No edit summary

19:4419:44, 23 June 2022 diff hist +3,558‎ N Lonapegsomatropin-tcgd ‎ Created page with "{{DrugProjectFormSinglePage |authorTag=Tejasvi Aryaputra |genericName=Lonapegsomatropin-tcgd |aOrAn=a |drugClass=human growth hormone |indicationType=treatment |indication=short stature due to inadequate secretion of endogenous growth hormone |adverseReactions=pyrexia, vomiting, abdominal pain, viral infection, nausea, arthralgia, hemorrhage, arthritis, and hemorrhage |blackBoxWarningTitle='''TITLE</spa..."

20:4320:43, 21 June 2022 diff hist +563‎ Mobocertinib ‎No edit summary current
18:2018:20, 21 June 2022 diff hist +39‎ Mobocertinib ‎No edit summary
18:1518:15, 21 June 2022 diff hist +4,311‎ Mobocertinib ‎No edit summary
18:0618:06, 21 June 2022 diff hist +1,585‎ Mobocertinib ‎No edit summary

20:1820:18, 15 June 2022 diff hist 0‎ N File:Mobocertinib Table 5 Efficacy.png ‎No edit summary current
20:1820:18, 15 June 2022 diff hist 0‎ N File:Mobocertinib Table 4 Adverse Reactions Lab Abnormalties.png ‎No edit summary current
20:1820:18, 15 June 2022 diff hist 0‎ N File:Mobocertinib Table 3 Adverse Reactions.png ‎No edit summary current
20:1720:17, 15 June 2022 diff hist 0‎ N File:Mobocertinib Table 2 Dosage for Adverse Reactions Pt.2.png ‎No edit summary current
20:1720:17, 15 June 2022 diff hist 0‎ N File:Mobocertinib Table 2 Dosage for Adverse Reactions.png ‎No edit summary current
20:1720:17, 15 June 2022 diff hist 0‎ N File:Mobocertinib Table 1 Dosage.png ‎No edit summary current
20:1620:16, 15 June 2022 diff hist 0‎ N File:Mobocertinib Structure.png ‎No edit summary current
20:1620:16, 15 June 2022 diff hist 0‎ N File:Mobocertinib Label Pt.2.png ‎No edit summary current
20:1620:16, 15 June 2022 diff hist 0‎ N File:Mobocertinib Label.png ‎No edit summary current
20:1520:15, 15 June 2022 diff hist 0‎ N File:Mobocertinib Drug Label.png ‎No edit summary current
20:1520:15, 15 June 2022 diff hist 0‎ N File:Mobocertinib Drug Interactions 3.png ‎No edit summary current
20:1520:15, 15 June 2022 diff hist 0‎ N File:Mobocertinib Drug Interactions 2.png ‎No edit summary current
20:1420:14, 15 June 2022 diff hist 0‎ N File:Mobocertinib Drug Interactions 1.png ‎No edit summary current
20:1320:13, 15 June 2022 diff hist 0‎ N File:Mobocertinib Drug Dosage.png ‎No edit summary current
19:4919:49, 15 June 2022 diff hist +2,851‎ Mobocertinib ‎No edit summary

20:5420:54, 14 June 2022 diff hist +2,635‎ Mobocertinib ‎No edit summary

19:4419:44, 10 June 2022 diff hist +5,912‎ Mobocertinib ‎No edit summary
14:5014:50, 10 June 2022 diff hist +1,213‎ Mobocertinib ‎No edit summary

User contributions for Tejasvi Aryaputra

7 February 2023

20 January 2023

18 January 2023

11 January 2023

10 January 2023

5 January 2023

3 January 2023

29 December 2022

12 September 2022

6 September 2022

5 September 2022

30 August 2022

25 August 2022

23 August 2022

22 August 2022

5 August 2022

3 August 2022

2 August 2022

1 August 2022

28 July 2022

26 July 2022

25 July 2022

22 July 2022

21 July 2022

18 July 2022

15 July 2022

14 July 2022

13 July 2022

12 July 2022

11 July 2022

8 July 2022

6 July 2022

5 July 2022

4 July 2022

1 July 2022

27 June 2022

23 June 2022

21 June 2022

15 June 2022

14 June 2022

10 June 2022

Navigation menu